Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology.

稳态视觉诱发电位（ssVEP）显示治疗眼刺激后视觉皮层反应显著增强。家长报告治疗后患儿追踪物体、识别颜色、独立移动等能力显著提升。患儿治疗眼的视网膜外层结构保留更好，厚度优于未治疗眼。

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its breakthrough approach, Fuse Vectors aims to be the universal solution for AAV ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. MeiraGTx is ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...